102 related articles for article (PubMed ID: 10607740)
41. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.
Conway K; Edmiston SN; Cui L; Drouin SS; Pang J; He M; Tse CK; Geradts J; Dressler L; Liu ET; Millikan R; Newman B
Cancer Res; 2002 Apr; 62(7):1987-95. PubMed ID: 11929815
[TBL] [Abstract][Full Text] [Related]
42. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma.
Romano G; Garagnani L; Boninsegna A; Ferrari P; Flamini G; De Gaetani C; Sgambato A; Giovanni F; Curigliano G; Ferretti G; Cittadini A; Trentini G
Anticancer Res; 1999; 19(5C):4571-6. PubMed ID: 10650812
[TBL] [Abstract][Full Text] [Related]
43. Distribution of p53 and K-ras mutations in human lung cancer tissues.
Gao HG; Chen JK; Stewart J; Song B; Rayappa C; Whong WZ; Ong T
Carcinogenesis; 1997 Mar; 18(3):473-8. PubMed ID: 9067544
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
45. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers.
Huang CC; Cheng YW; Chen MC; Lin YS; Chou MC; Lee H
Environ Mol Mutagen; 2006 Aug; 47(7):527-32. PubMed ID: 16721749
[TBL] [Abstract][Full Text] [Related]
46. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
47. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
49. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
50. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
52. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
[TBL] [Abstract][Full Text] [Related]
53. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours.
Warren W; Biggs PJ; el-Baz M; Ghoneim MA; Stratton MR; Venitt S
Carcinogenesis; 1995 May; 16(5):1181-9. PubMed ID: 7767983
[TBL] [Abstract][Full Text] [Related]
54. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
55. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.
Waber PG; Chen J; Nisen PD
Cancer Res; 1993 Dec; 53(24):6028-30. PubMed ID: 8261417
[TBL] [Abstract][Full Text] [Related]
56. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
57. Comparative analysis of p53 mutations in bladder washings and histologic specimens.
Vet JA; Hessels D; Marras SA; van de Kaa CA; van der Poel HG; Michalides RJ; Debruyne FM; Schalken JA
Am J Clin Pathol; 1998 Nov; 110(5):647-52. PubMed ID: 9802351
[TBL] [Abstract][Full Text] [Related]
58. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.
Dalbagni G; Presti JC; Reuter VE; Zhang ZF; Sarkis AS; Fair WR; Cordon-Cardo C
Diagn Mol Pathol; 1993 Mar; 2(1):4-13. PubMed ID: 7904525
[TBL] [Abstract][Full Text] [Related]
59. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of mutations in the p53 gene in superficial bladder cancer.
Dahse R; Utting M; Werner W; Schubert J; Claussen U; Junker K
Oncol Rep; 2000; 7(5):931-6. PubMed ID: 10948316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]